The Investor Relations website contains information about Auspex Pharmaceuticals business for stockholders, potential investors, and financial analysts.
http://investor.auspexpharma.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Thursday
LOAD TIME
0.6 seconds
PAGES IN
THIS WEBSITE
0
SSL
EXTERNAL LINKS
7
SITE IP
206.200.251.19
LOAD TIME
0.578 sec
SCORE
6.2
Investor Relations - Auspex Pharmaceuticals | investor.auspexpharma.com Reviews
https://investor.auspexpharma.com
The Investor Relations website contains information about Auspex Pharmaceuticals business for stockholders, potential investors, and financial analysts.
Pipeline | Auspex Pharmaceuticals
http://www.auspexpharma.com/pipeline
For Patients & Family. Events & Presentations. Financials & Filings. Press Releases / Events. Auspex's lead compound, SD-809, is being developed for the treatment of the involuntary movements that characterize several neurological disorders including Huntington's Disease, Tourette Syndrome and Tardive Dyskinesia. Deuterium-containing pirfenidone analog (SD-560).
News/Events Auspex | Auspex Pharmaceuticals
http://www.auspexpharma.com/news-events
For Patients & Family. Events & Presentations. Financials & Filings. Press Releases / Events. Auspex's lead compound, SD-809, is being developed for the treatment of the involuntary movements that characterize several neurological disorders including Huntington's disease, Tourette syndrome and tardive dyskinesia. Press Releases / Events. January 01, 1970. 124; read more. January 01, 1970. 124; read more.
Investors | Auspex Pharmaceuticals
http://www.auspexpharma.com/about-auspex/investors
For Patients & Family. Events & Presentations. Financials & Filings. Press Releases / Events. Auspex's lead compound, SD-809, is being developed for the treatment of the involuntary movements that characterize several neurological disorders including Huntington's Disease, Tourette Syndrome and Tardive Dyskinesia. Auspex Pharmaceuticals’ investors include Thomas, McNerney and Partners, CMEA Capital, Panorama Capital, Sloan Biotech Funds and BioMed Ventures.
For Patients and Families | Huntington's Disease | Auspex Pharmaceuticals
http://www.auspexpharma.com/for-patients-and-family
For Patients & Family. Events & Presentations. Financials & Filings. Press Releases / Events. Auspex's lead compound, SD-809, is being developed for the treatment of the involuntary movements that characterize several neurological disorders including Huntington's disease, Tourette syndrome and tardive dyskinesia. For Patients and Family. Presentation of SD-809 for the Treatment of Chorea Associated with Huntington's Disease. June 22, 2013. Huntington's Disease Society of America.
Clinical Trials | Huntington's Disease | Auspex Pharmaceuticals
http://www.auspexpharma.com/clinical-trials
For Patients & Family. Events & Presentations. Financials & Filings. Press Releases / Events. Auspex's lead compound, SD-809, is being developed for the treatment of the involuntary movements that characterize several neurological disorders including Huntington's Disease, Tourette Syndrome and Tardive Dyskinesia. Ongoing Clinical Development of SD-809. Phase 3 placebo-controlled registration trial. Open-label switch and long-term safety clinical trial. Phase 1b clinical trial in Tourette syndrome.
About Auspex | Auspex Pharmaceuticals
http://www.auspexpharma.com/about-auspex
For Patients & Family. Events & Presentations. Financials & Filings. Press Releases / Events. Auspex's lead compound, SD-809, is being developed for the treatment of the involuntary movements that characterize several neurological disorders including Huntington's Disease, Tourette Syndrome and Tardive Dyskinesia.
For Clinicians | Huntington's Disease | Auspex Pharmaceuticals
http://www.auspexpharma.com/for-clinicians
For Patients & Family. Events & Presentations. Financials & Filings. Press Releases / Events. Auspex's lead compound, SD-809, is being developed for the treatment of the involuntary movements that characterize several neurological disorders including Huntington's Disease, Tourette Syndrome and Tardive Dyskinesia. Clinical Studies for Huntington’s Disease. First Time Use of SD-809 in Huntington Disease (First-HD) read more.
TOTAL LINKS TO THIS WEBSITE
7
404 - PAGE NOT FOUND
ERROR 404 - PAGE NOT FOUND. Why am I seeing this page? 404 means the file is not found. If you have already uploaded the file then the name may be misspelled or it is in a different folder. You may get a 404 error for images because you have Hot Link Protection turned on and the domain is not on the list of authorized domains. It is also possible that you have inadvertently deleted your document root or the your account may need to be recreated. Either way, please contact your web host immediately. When ...
Investor Project Immobilie als Kapitalanlage Wien
At Home
Skip to main content. Ideas and How To's. Skip to main content. Ideas and How To's. Any style. Any budget. Any reason to redecorate. Any style. Any budget. Any reason to redecorate. Any style. Any budget. Any reason to redecorate. Any style. Any budget. Any reason to redecorate. Any style. Any budget. Any reason to redecorate. Why invest in At Home? Launched At Home brand in fiscal year 2015, driving 8.3%. Comparable store sales in that year. Why invest in At Home? Why invest in At Home? Jan 09, 2017.
Welcome to Audiovox - Investor Relations - Investor Overview
160;- 0.07. Data as of 08/07/15 4:00 pm ET. Minimum 20 minute delay. VOXX International Corporation To Present At The Oppenheimer and Co. 18th Annual Technology, Internet and Communications Conference. VOXX International Corporation Directors Elected At Annual Shareholders Meeting. VOXX International Corporation Reports Fiscal 2016 First Quarter Financial Results. VOXX International Corporation Sets Date For Its Fiscal 2016 First Quarter Results And Conference Call. There are currently no events scheduled.
Welcome to Ausbil Investor Web Site
Welcome to the Ausbil Investor website. Now that you have registered you will need to Login. Please note that you can login to Ausbil Investor from a web browser on any computer anywhere. How do I get Access? Having trouble logging in. To login to Ausbil Investor:. 1 In the appropriate fields, type in your email address and put in a password. 2 Click the 'Sign In' button. If the supplied details are correct, you will be logged into your secure Ausbil Investor session.
Investor Relations - Auspex Pharmaceuticals
For Patients and Family. Auspex's lead compound, SD-809, is being developed for the treatment of the involuntary movements that characterize several neurological disorders including Huntington's Disease, Tourette Syndrome and Tardive Dyskinesia. Auspex (Nasdaq: ASPX) was founded in 2001 and is headquartered in San Diego, California. 4:00 PM ET on May 4, 2015. Delayed at least 20 minutes. May 5, 2015. Teva Completes Acquisition of Auspex Pharmaceuticals. Mar 30, 2015. View all press releases ».
Company Overview :: Investors :: Austal
Austal - Leading the World in the Design and Construction of Customised Aluminium Commercial and Defence Vessels. Our People in Action. Customer / Operator Links. Leisure and Tourism Products. Careers at Austal Australia. Careers at Austal USA. Inspired by the diversity of our customers and the challenge to exceed their expectations, Austal has, for over 25 years, designed, delivered and supported an unrivalled portfolio of high performance commercial and defence ships. Customer / Operator Links.
Overview >
Autobytel Inc. (NASDAQ: ABTL. View all ». Aug 6, 2015. Autobytel Reports Second Quarter 2015 Results. Jul 24, 2015. Autobytel to Hold Second Quarter Conference Call on Thursday, August 6, 2015 at 5:00 pm ET. Jul 21, 2015. Autobytel Sponsors Working Wardrobes and VetNet to Help Veterans Find Jobs and Achieve Self-Sufficiency. Onclick="window.open('http:/ delicious.com/save? V=5&noui&jump=close&url=http:/ investor.autobytel.com/index.cfm? U=http:/ investor.autobytel.com/index.cfm? Liolios Group, Inc.
Automic Registries
A browser upgrade is required. We have detected that you are using an older version of Internet Explorer which isn’t supported. Please click here. To upgrade to the latest version, or download a compatible browser using the icons below.
For Investors | Aveo
Scientific Publications and Presentations. AVEO Oncology is a biopharmaceutical company committed to developing targeted therapies through biomarker-driven insights to provide substantial improvements in patient outcomes where significant unmet medical needs exist. AVEO’s proprietary Human Response Platform has delivered unique insights into cancer and related disease biology that are being leveraged in the clinical development of its therapeutic candidates. 160; 0.03. 08/07/15 4:00 pm ET.
Investor Relations - AeroVironment, Inc.
Battery and Fuel Cell Systems. Clean Energy and Water. Digital Data Link (DDL). AV Decision Support System (DSS). Energy, Transportation and Infrastructure. AV Decision Support System (DSS). EV Solutions for Business. EV Solutions for Home. Industrial Charging for MHE. Industrial Charging for GSE. Power Cycling and Test Systems. Mar 26, 2018. AeroVironment Releases New Puma 3, Upgraded for Operation in More Challenging Radio Frequency Environments. Mar 6, 2018. View all press releases ». Jun 26, 2018.
SOCIAL ENGAGEMENT